Literature DB >> 1491735

Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease.

K M Schegg1, L S Harrington, S Neilsen, R M Zweig, J H Peacock.   

Abstract

In order to determine the effect of Alzheimer's disease on the relative distribution of soluble and membrane-bound molecular forms of acetylcholinesterase (AChE) in the brain, postmortem samples (delay interval less than 12 h) were obtained from parietal cortex (Brodmann area 40) and hippocampus as well as the areas containing their respective projection nuclei, i.e., substantia innominata and septal nucleus, in 9 patients with Alzheimer's disease (AD) and 4 normal controls. The monomer (G1), dimer (G2), and tetramer (G4) forms of AChE were examined. In AD compared to controls, significant changes occurred in area 40 and hippocampus but not in the areas containing projection nuclei, and included loss of mean total AChE activity, decrease in the relative percentage of membrane-bound G4, and increase in the relative percentage of soluble G1-G2. Percent of soluble G4 was unaffected in AD brain. In area 40 but not hippocampus a large increase in percent membrane-bound G1-G2 occurred. Thus, these results emphasize that the selective decrease in membrane-bound G4 accounts for the decrease in total G4 activity in AD brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491735     DOI: 10.1016/0197-4580(92)90092-c

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

Review 1.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

2.  In vivo localization of human acetylcholinesterase-derived species in a β-sheet conformation at the core of senile plaques in Alzheimer's disease.

Authors:  Létitia Jean; Stephen Brimijoin; David J Vaux
Journal:  J Biol Chem       Date:  2019-02-20       Impact factor: 5.157

3.  Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

Authors:  George T Grossberg
Journal:  Curr Ther Res Clin Exp       Date:  2003-04

4.  Cholinergic depletion and basal forebrain volume in primary progressive aphasia.

Authors:  Jolien Schaeverbeke; Charlotte Evenepoel; Rose Bruffaerts; Koen Van Laere; Guy Bormans; Eva Dries; Thomas Tousseyn; Natalie Nelissen; Ronald Peeters; Mathieu Vandenbulcke; Patrick Dupont; Rik Vandenberghe
Journal:  Neuroimage Clin       Date:  2016-12-02       Impact factor: 4.881

Review 5.  Expression and Function of the Cholinergic System in Immune Cells.

Authors:  Takeshi Fujii; Masato Mashimo; Yasuhiro Moriwaki; Hidemi Misawa; Shiro Ono; Kazuhide Horiguchi; Koichiro Kawashima
Journal:  Front Immunol       Date:  2017-09-06       Impact factor: 7.561

6.  Central Administration of Ampelopsin A Isolated from Vitis vinifera Ameliorates Cognitive and Memory Function in a Scopolamine-Induced Dementia Model.

Authors:  Yuni Hong; Yun-Hyeok Choi; Young-Eun Han; Soo-Jin Oh; Ansoo Lee; Bonggi Lee; Rebecca Magnan; Shi Yong Ryu; Chun Whan Choi; Min Soo Kim
Journal:  Antioxidants (Basel)       Date:  2021-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.